Related Experiment Video

Updated: Mar 7, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

8.3K

Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape

R Costa1, B A Carneiro1, D A Wainwright2

  • 1Developmental Therapeutics Program, Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|February 9, 2017
PubMed

Insights

Breast cancer metastasis to the central nervous system (CNS) is common in HER2+ or triple-negative types. Understanding CNS metastasis biology and blood-brain barrier interactions is key for new breast cancer therapies.

Area of Science:

  • Oncology
  • Neuro-oncology
  • Translational Medicine

Background:

  • Breast cancer is a leading cause of central nervous system (CNS) metastasis.
  • Patients with HER2-positive (HER2+) or triple-negative breast cancer face the highest risk of CNS metastasis and poor prognosis.
  • Current treatments for CNS metastasis often show limited efficacy.

Purpose of the Study:

  • To review recent discoveries in the biology of breast cancer brain metastases.
  • To summarize clinical progress in treating breast cancer CNS metastasis.
  • To propose rational approaches for future investigational therapies.

Main Methods:

  • Literature review of recent scientific discoveries.
  • Analysis of clinical progress in breast cancer CNS metastasis.
  • Synthesis of information to suggest future therapeutic strategies.

Main Results:

  • Advances in understanding breast cancer biology have improved survival for some metastatic patients.
  • Significant challenges remain in treating CNS metastasis, including understanding its biology and overcoming the blood-brain barrier.
  • HER2+ and triple-negative breast cancers are particularly prone to CNS metastasis.

Conclusions:

  • Further research into the biological nuances of breast cancer brain metastases is crucial.
  • Improving the interaction of novel compounds with the blood-brain barrier is essential for effective treatment.
  • Rational investigational therapies are needed to improve outcomes for patients with breast cancer CNS metastasis.

More Related Videos

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

28.3K
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
995
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
701